Novel biomarkers and interferon signature in secondary progressive multiple sclerosis

Area of Science:

• Neuroimmunology
• Genomics
• Neurodegenerative Diseases

Background:

• Multiple sclerosis (MS) is characterized by immune dysregulation and impaired interferon-beta (IFN-β) signaling.
• Secondary Progressive MS (SPMS) presents with progressive neurodegeneration and reduced treatment efficacy.
• Relapsing-Remitting MS (RRMS) and SPMS show distinct molecular profiles compared to healthy individuals.

Purpose of the Study:

• To investigate gene expression differences in RRMS and SPMS.
• To identify potential biomarkers for immune regulation and neurodegeneration in MS.
• To evaluate the effect of IFN-β treatment on gene expression in SPMS.

Main Methods:

• Differential gene expression analysis comparing RRMS, SPMS, and healthy controls.
• Analysis of serum protein balance (Th1/Th2).
• Assessment of gene expression changes following IFN-β treatment in SPMS patients.

Main Results:

• RRMS exhibited 8700 differentially expressed genes (DEG) compared to controls, while SPMS showed 3900 DEG.
• SPMS had lower expression of olfactory receptor, WNT/ß-catenin, and metallothionein genes compared to RRMS.
• IFN-β treatment reduced pro-inflammatory gene expression and increased metallothionein gene expression in SPMS.

Conclusions:

• Gene expression patterns differentiate MS subtypes and offer insights into disease mechanisms.
• Olfactory receptor, WNT/ß-catenin, and metallothionein pathways are implicated in MS progression.
• IFN-β demonstrates potential for modulating immune responses and promoting repair in SPMS through gene expression changes.